Search company, investor...



Other Investors | Alive

About Evogenix

Evogenix aims to provide advanced technologies to provide powerful new antibody therapeutics for world markets.

Headquarters Location

37 Epping Road Level 2



(+6) 128-061-9900

Missing: Evogenix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Evogenix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Evogenix Patents

Evogenix has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Virus families, Transcription factors, Monoclonal antibodies, Molecular biology


Application Date


Grant Date



Related Topics

Clusters of differentiation, Virus families, Transcription factors, Monoclonal antibodies, Molecular biology



Evogenix Frequently Asked Questions (FAQ)

  • What is Evogenix's latest funding round?

    Evogenix's latest funding round is Other Investors.

  • Who are the investors of Evogenix?

    Investors of Evogenix include Bluebox Security.

  • Who are Evogenix's competitors?

    Competitors of Evogenix include Perseus Proteomics, Kereos, CoImmune, GANYMED Pharmaceuticals, Affimed Therapeutics and 10 more.

Compare Evogenix to Competitors

AdAlta Logo

Which is using a platform-technology approach to develop antibody and peptide-based therapeutics against select targets.

Femta Pharmaceuticals

Femta is developing a new generation of antibody therapeutics for major disease indications.


Recodgen is developing therapeutics targeting genetic expressions to disease

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.


Chimeros is developing a biologics approach to enable delivery of polynucleotide therapeutics such as siRNAs. The company's delivery technology, termed Chimerasomes, is based upon protein building blocks that can bind these therapeutic payloads and subsequently be triggered to self-assemble into nanocages, thereby encapsulating the polynucleic acids. The surface of the nanocages can subsequently be decorated with targeting moieties such as antibodies or with PK/ biodistribution modulating molecules such as PEG polymers and lipid coatings.


ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). The company use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR offers custom phage display services.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.